Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.

The selective pharmacology of the selective serotonin reuptake inhibitors (SSRIs) results in a lower potential for pharmacodynamic drug interactions relative to other antidepressants such as the tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). However, the SSRIs have been implicated in the development of the serotonin syndrome--a potentially life-threatening complication of treatment with psychotropic drugs. The syndrome is produced most often by the concurrent use of two or more drugs that enhance central nervous system serotonin activity and often goes unrecognized because of the varied and nonspecific nature of its clinical features. The serotonin syndrome is characterized by alterations in cognition (disorientation, confusion), behavior (agitation, restlessness), autonomic nervous system function (fever, shivering, diaphoresis, diarrhea), and neuromuscular (ataxia, hyperreflexia, myoclonus) activity. The difference between this syndrome and the occurrence of adverse effects caused by serotonin reuptake inhibitors alone is the clustering of the signs and symptoms, their severity, and their duration. There are important pharmacokinetic interactions between SSRIs and other serotonergic drugs due principally to their effects on the cytochrome P450(CYP) isoenzymes, the potential for which varies widely amongst the SSRI group, which may increase the likelihood of a pharmacodynamic interaction. The exceptionally long washout period required after fluoxetine discontinuation may cause additional problems and/or inconvenience. Patients with serotonin syndrome usually respond to discontinuation of drug therapy and supportive care alone, but they may also require treatment with antiserotonergic agent such as cyproheptadine, methysergide, and/or propranolol. To reduce the occurrence, morbidity, and mortality of the serotonin syndrome, it must be both prevented by prudent pharmacotherapy and given prompt recognition when it is present.

[1]  A. Szegedi,et al.  Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. , 1996, The Journal of clinical psychiatry.

[2]  D. Nierenberg,et al.  The central nervous system serotonin syndrome , 1993, Clinical pharmacology and therapeutics.

[3]  R. Sandyk L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine. , 1986, Journal of clinical psychopharmacology.

[4]  A. Sleight,et al.  Relationship between extracellular 5‐hydroxytryptamine and behaviour following monoamine oxidase inhibition and l‐tryptophan , 1988, British journal of pharmacology.

[5]  P. Nijhawan,et al.  Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission. , 1996, Critical care medicine.

[6]  HarveyA. Sternbach DANGER OF MAOI THERAPY AFTER FLUOXETINE WITHDRAWAL , 1988, The Lancet.

[7]  P. Blier,et al.  The safety of concomitant use of sumatriptan and antidepressant treatments. , 1995, Journal of clinical psychopharmacology.

[8]  M. Robbins,et al.  Sertraline intoxication in a child. , 1994, Annals of emergency medicine.

[9]  A. Nierenberg,et al.  Trazodone for antidepressant-associated insomnia. , 1994, The American journal of psychiatry.

[10]  O. Spigset,et al.  Serotonin syndrome caused by a moclobemide-clomipramine interaction. , 1993, BMJ.

[11]  D. Coulter,et al.  Hypertension with moclobemide , 1995, The Lancet.

[12]  I. Boyd Hypertension with moclobemide , 1995, The Lancet.

[13]  P. Cowen,et al.  Fluoxetine and Suicidal Behaviour , 1992, British Journal of Psychiatry.

[14]  I. M. Vigran DANGEROUS POTENTIATION OF MEPERIDINE HYDROCHLORIDE BY PARGYLINE HYDROCHLORIDE. , 1964, JAMA.

[15]  R. Mitchell Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. , 1955, Annals of internal medicine.

[16]  G. Rutherford,et al.  Use of hospitals by patients with AIDS in San Francisco. , 1988, The New England journal of medicine.

[17]  A. Hadley,et al.  Mania resulting from lithium-fluoxetine combination. , 1989, The American journal of psychiatry.

[18]  S. Nimmo,et al.  Drug‐induced hyperthermia , 1993, Anaesthesia.

[19]  M. Corkeron Serotonin syndrome — a potentially fatal complication of antidepressant therapy , 1995, The Medical journal of Australia.

[20]  J. Dingemanse,et al.  Moclobemide and fluvoxamine co‐administration: A prospective study in healty volunteers to investigate the potential development of the ‘serotonin syndrome’ , 1995 .

[21]  A. Gelenberg Polypharmacy in Psychiatry , 1995 .

[22]  A. Salama,et al.  A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. , 1989, The American journal of psychiatry.

[23]  S. Preskorn,et al.  Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. , 1994, Journal of clinical psychopharmacology.

[24]  D. Murphy,et al.  Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. , 1991, Journal of clinical psychopharmacology.

[25]  R. Roth,et al.  3,4-Methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by L-tryptophan. , 1990, European journal of pharmacology.

[26]  D. Meyer,et al.  Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review. , 1981, Journal of clinical psychopharmacology.

[27]  R. Joffe,et al.  Combined SSRI-moclobemide treatment of psychiatric illness. , 1994, The Journal of clinical psychiatry.

[28]  M. Bauer,et al.  Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. , 1996, Journal of Clinical Psychopharmacology.

[29]  T. Lüscher,et al.  Endothelium-Derived Nitric Oxide, Endothelin, and Platelet Vessel Wall Interaction: Alterations in Hypercholesterolemia and Atherosclerosis , 1993, Seminars in thrombosis and hemostasis.

[30]  A. Freemont,et al.  Ecstasy, 3–4 Methylenedioxymethamphetamine (MDMA), a Fatality Associated with Coagulopathy and Hyperthermia , 1991, Journal of the Royal Society of Medicine.

[31]  S. Toyama,et al.  Is it Safe to Combine a Selective Serotonin Reuptake Inhibitor with Selegiline? , 1994, The Annals of pharmacotherapy.

[32]  D. Ames,et al.  Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome--a possible link? , 1993, JAMA.

[33]  A. Shah,et al.  Case report: Acute confusional state secondary to a combination of fluoxetine and lithium , 1992 .

[34]  S. Platman,et al.  Potentiation of a monoamine oxidase inhibitor by tryptophan. , 1969, Journal of psychiatric research.

[35]  R. Zerbe,et al.  Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. , 1993, Journal of clinical psychopharmacology.

[36]  M. Leung,et al.  Lack of an Interaction Between Sumatriptan and Selective Serotonin Reuptake Inhibitors , 1995, Headache.

[37]  O. Suchowersky,et al.  Interaction of Fluoxetine and Selegiline , 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[38]  W. Harrison,et al.  Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? , 1995, The Journal of clinical psychiatry.

[39]  R. Lappin,et al.  Treatment of the serotonin syndrome with cyproheptadine. , 1994, The New England journal of medicine.

[40]  N. C. Reid,et al.  Pethidine and Phenelzine , 1962 .

[41]  J. Osterloh,et al.  Multiple severe complications from recreational ingestion of MDMA ('Ecstasy') , 1987, JAMA.

[42]  G. Keepers,et al.  Interaction of fluoxetine and pentazocine. , 1990, The American journal of psychiatry.

[43]  K. Otani,et al.  Inhibition of Trazodone Metabolism by Thioridazine in Humans , 1995, Therapeutic drug monitoring.

[44]  Joffe Rt,et al.  An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. , 1993 .

[45]  S. Dursun,et al.  Toxic serotonin syndrome after fluoxetine plus carbamazepine , 1993, The Lancet.

[46]  F. Ruiz Fluoxetine and the serotonin syndrome. , 1994, Annals of emergency medicine.

[47]  Coplan Jd,et al.  Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. , 1993 .

[48]  G. Kaskey Possible interaction between an MAOI and "ecstasy". , 1992, The American journal of psychiatry.

[49]  J. Feighner,et al.  Adverse consequences of fluoxetine-MAOI combination therapy. , 1990, The Journal of clinical psychiatry.

[50]  A. Delini-Stula,et al.  Risk of 5-HT syndrome after co-administration of moclobemide (RIMA) and selective 5-HT re-uptake inhibitors (SSRI) — analysis of cases , 1993, European Neuropsychopharmacology.

[51]  W. Steiner,et al.  Toxic reaction following the combined administration of fluoxetine and l-tryptophan: Five case reports , 1986, Biological Psychiatry.

[52]  D. Steffens,et al.  Serotonin syndrome produced by a combination of fluoxetine and lithium. , 1993, The American journal of psychiatry.

[53]  S. Sindrup,et al.  Citalopram: Interaction Studies with Levomepromazine, Imipramine, and Lithium , 1993, Therapeutic drug monitoring.

[54]  H. Sternbach The serotonin syndrome. , 1991, The American journal of psychiatry.

[55]  Noveske Fg,et al.  Possible toxicity of combined fluoxetine and lithium. , 1989 .

[56]  M. Baetz,et al.  Serotonin Syndrome from Fluvoxamine and Buspirone , 1995, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[57]  L. Bowen Fatal Hyperpyrexia with Antidepressant Drugs , 1964, British medical journal.

[58]  K. Nisijima,et al.  Cerebrospinal fluid monoamine metabolism in a case of neuroleptic malignant syndrome improved by electroconvulsive therapy , 1996, Biological Psychiatry.

[59]  O. Spigset,et al.  Serotonin syndrome induced by fluvoxamine-lithium interaction. , 1993, Pharmacopsychiatry.

[60]  D. Jermain,et al.  Potential Fluoxetine—Selegiline Interaction , 1992, The Annals of pharmacotherapy.

[61]  J. Dingemanse An update of recent moclobemide interaction data , 1993, International clinical psychopharmacology.

[62]  D. Baldwin,et al.  Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions , 1994, International clinical psychopharmacology.

[63]  D. Goldbloom,et al.  Fluoxetine and neuroleptic malignant syndrome , 1990, Biological Psychiatry.

[64]  A. Sjoerdsma,et al.  Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor , 1960, Neurology.

[65]  U. Davies,et al.  Landmarks for the insertion of oesophageal endoprosthesis. , 1992 .

[66]  S. Zail,et al.  Effect of ethanol on liver 8-aminolaevulinate synthetase in rats. , 1968 .

[67]  J. Shee Dangerous Potentiation of Pethidine by Iproniazid, and its Treatment , 1960, British medical journal.

[68]  L. Kofoed,et al.  Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting. , 1994, American journal of hospital pharmacy.

[69]  B. Rumack,et al.  A case of MAO inhibitor/MDMA interaction: agony after ecstasy. , 1987, Journal of toxicology. Clinical toxicology.

[70]  Philip R. Cohen,et al.  Lithium in Tricyclic-Resistant Depression Correlation of Increased Brain 5-HT Function with Clinical Outcome , 1991, British Journal of Psychiatry.

[71]  A. Ontiveros,et al.  Refractory depression: the addition of lithium to fluoxetine or desipramine , 1991, Acta psychiatrica Scandinavica.

[72]  B. Seitanidis,et al.  T LYMPHOCYTES IN INFECTIOUS MONONUCLEOSIS , 1974 .

[73]  G. Simpson,et al.  Combined MAOI-tricyclic antidepressant treatment: a reevaluation. , 1981, Journal of clinical psychopharmacology.

[74]  G. Addonizio,et al.  Reinduction of Neuroleptic Malignant Syndrome by Lithium , 1987, Journal of clinical psychopharmacology.

[75]  K. Wozniak,et al.  Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors , 1983, Psychological Medicine.

[76]  T. Dinan,et al.  Lithium augmentation in sertraline‐resistant depression: a preliminary dose‐response study , 1993, Acta psychiatrica Scandinavica.

[77]  D. Taylor ALARMING REACTION TO PETHIDINE IN PATIENTS ON PHENELZINE , 1962 .

[78]  A. T. Harvey,et al.  Comment on: the serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. , 1995, The American journal of emergency medicine.

[79]  M. Lejoyeux,et al.  Serotonin Syndrome , 1994 .

[80]  S. Dawling,et al.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.

[81]  M. Graber,et al.  Sertraline-Phenelzine Drug Interaction: A Serotonin Syndrome Reaction , 1994, The Annals of pharmacotherapy.

[82]  O. Rascol,et al.  Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline , 1993, The Lancet.

[83]  L. Baxter,et al.  The serotonin syndrome: case responsive to propranolol. , 1986, Journal of clinical psychopharmacology.

[84]  W. Bushnell,et al.  A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. , 1995, The Journal of clinical psychiatry.

[85]  M. Marino,et al.  Interaction of nefazodone (N) and fluoxetine (F) , 1996 .

[86]  M. Norden Buspirone treatment of sexual dysfunction associated with selective serotonin re‐uptake inhibitors , 1994 .

[87]  H. Palmer Potentiation of Pethidine , 1960 .

[88]  D. Marazziti,et al.  Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage. , 1993, Pharmacopsychiatry.

[89]  Achamallah Ns VISUAL HALLUCINATIONS AFTER COMBINING FLUOXETINE AND DEXTROMETHORPHAN , 1992 .

[90]  E. Azmitia,et al.  The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. , 1992, European journal of pharmacology.

[91]  R. Reeves,et al.  Serotonin syndrome produced by paroxetine and low-dose trazodone. , 1995, Psychosomatics.

[92]  R. Goldberg,et al.  Serotonin syndrome from trazodone and buspirone. , 1992, Psychosomatics.

[93]  K. Bergmann,et al.  Combination Treatment with Noradrenalin and Serotonin Reuptake Inhibitors in Resistant Depression , 1992, British Journal of Psychiatry.

[94]  T. R. Brodribb,et al.  Efficacy and adverse effects of moclobemide , 1994, The Lancet.

[95]  H. Wildgust,et al.  The combination of fluoxetine and lithium in clinical practice , 1993, International clinical psychopharmacology.

[96]  W. Haefely,et al.  Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor. , 1983, Modern problems of pharmacopsychiatry.

[97]  C. Bowden,et al.  Sertraline and isocarboxazid cause a serotonin syndrome. , 1994, Journal of clinical psychopharmacology.

[98]  S. Dursun,et al.  Toxic serotonin syndrome or extrapyramidal side-effects? , 1995, British Journal of Psychiatry.

[99]  G. Screaton,et al.  Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse , 1992, The Lancet.

[100]  M. Floris,et al.  A CONTROLLED PILOT STUDY OF THE COMBINATION OF FLUVOXAMINE AND LITHIUM , 1991 .

[101]  P. Waller,et al.  Safety of fluoxetine: Comparison with fluvoxamine , 1992 .

[102]  R. Tackley,et al.  Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction , 1987, Anaesthesia.

[103]  T. M. Brown,et al.  The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. , 1994, The American journal of emergency medicine.

[104]  J. Lieberman,et al.  Neuromuscular effects of monoamine oxidase inhibitors. , 1985, Journal of clinical psychopharmacology.

[105]  R. Bost,et al.  'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. , 1987, JAMA.

[106]  A. Ceccherini-Nelli,et al.  Fluoxetine: the relationship between response, adverse events, and plasma concentrations in the treatment of bulimia nervosa , 1993, International clinical psychopharmacology.

[107]  C. Callaway,et al.  Hyperthermia in psychostimulant overdose. , 1994, Annals of emergency medicine.

[108]  J. Dingemanse Pharmacological interactions with reversible MAOIs and clinical relevance , 1993, European Neuropsychopharmacology.

[109]  D. Faulds,et al.  Moclobemide : A Review of its Pharmacological Properties and Therapeutic Use in Depressive Illness. , 1992, Drugs.

[110]  C. Lowenstein,et al.  Nitric Oxide: A Physiologic Messenger , 1994, Annals of Internal Medicine.

[111]  P. Neuvonen,et al.  Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses , 1993, The Lancet.

[112]  M. Evans,et al.  Fluvoxamine and lithium: an unusual interaction , 1990, British Journal of Psychiatry.

[113]  H. Miyaoka,et al.  Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders? , 1995, International clinical psychopharmacology.

[114]  T. Randall Ecstasy-fueled 'rave' parties become dances of death for English youths. , 1992, JAMA.

[115]  N. Rivers,et al.  Possible lethal reaction between nardil and dextromethorphan. , 1970, Canadian Medical Association journal.

[116]  G. Tucker,et al.  The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. , 1992, British journal of clinical pharmacology.

[117]  Schen Rj Letter: Chlorpropamide hypoglycaemia. , 1973 .